XENEXenon Pharmaceuticals Inc.
Price
-1.4%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality strong, nothing alarming, growth fading, the market undecided.
We are a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need. We are advancing a differentiated product pipeline led by our investigational candidate, azetukalner, which is being studied in multiple Phase 3 studies in epilepsy, major depressive disorder, or MDD, and bipolar depression, or BPD. Our early-stage pipeline includes Kv7 potassium channel openers and Nav sodium channel modulators being advanced for select high‑need indications, including pain.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Xenon Pharmaceuticals Inc. (XENE) reported revenue of $0 in Q2 2026 (quarter ended Jun 30, 2026). That came with net loss of $111M. For the full year FY2025, revenue was $7.5M and net income −$346M. The next results filing is expected around Nov 2, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026Xenon Reports Q2 2026 Financial Results and Provides Business Update.Earnings release · press release
- May 7, 2026Xenon Reports Q1 2026 Financial Results and Provides Business Update.Earnings release · press release
- Apr 13, 2026On April 7, 2026, Xenon Pharmaceuticals Inc. (the “Company”) amended and restated the Company’s Amended and Restated 2025 Inducement Equity Incentive Plan (as amended and restated, the “2025 Inducement Plan”) to increase the maximum number of shares of its common stock reserved for issuance under the 2025 Inducement …Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.